JACC. Cardiovascular interventions最新文献

{"title":"Tear It Up!","authors":"Isida Byku MD , Robert Lederman MD , Vasilis Babaliaros MD","doi":"10.1016/j.jcin.2025.02.002","DOIUrl":"10.1016/j.jcin.2025.02.002","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 782-784"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiogenic Shock","authors":"David A. Baran MD, Antonio Lewis Camargo MD","doi":"10.1016/j.jcin.2025.01.001","DOIUrl":"10.1016/j.jcin.2025.01.001","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 702-704"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Results of Multicenter Trial of a Novel Balloon-Expandable Valve With Anchor for Aortic Regurgitation","authors":"Wenzhi Pan MD ,&nbsp;Shasha Chen MD ,&nbsp;Wei Li MD ,&nbsp;Xianbao Liu MD ,&nbsp;Yundai Chen MD ,&nbsp;Jianfang Luo MD ,&nbsp;Xiaogang Guo MD ,&nbsp;Yiqiang Yuan MD ,&nbsp;Ling Tao MD ,&nbsp;Yanqing Wu MD ,&nbsp;Yan Li MD ,&nbsp;Zhihui Zhang MD ,&nbsp;Shenghua Zhou MD ,&nbsp;Zhifu Guo MD ,&nbsp;Xiaofei Jiang MD ,&nbsp;Mingfei Li MD ,&nbsp;Shengda Chen PhD ,&nbsp;Jianan Wang MD, PhD ,&nbsp;Daxin Zhou MD ,&nbsp;Junbo Ge MD, PhD","doi":"10.1016/j.jcin.2024.12.006","DOIUrl":"10.1016/j.jcin.2024.12.006","url":null,"abstract":"<div><h3>Background</h3><div>The application of transfemoral transcatheter aortic valve replacement (TAVR) for patients with severe pure native aortic regurgitation (PNAR) is limited by a lack of dedicated devices. The Hanchor Valve system is the first transfemoral balloon-expandable transcatheter heart valve with an anchor element designed for PNAR.</div></div><div><h3>Objectives</h3><div>The aims of this report are to present the 30-day follow-up results of transfemoral TAVR using the Hanchor Valve system in patients with severe PNAR and to provide insights into the technical aspects of the procedure.</div></div><div><h3>Methods</h3><div>The HAVE AR (Multi-Center Trial of Hanchor Valve for Treating Patients With Severe Pure Native Aortic Regurgitation) trial is an ongoing, prospective, multicenter, single-arm, objective performance criteria registration study. Transfemoral TAVR using the Hanchor Valve system for treating severe PNAR was performed in patients with intermediate and high surgical risk. Procedural results and 30-day clinical and echocardiographic outcomes were collected and analyzed.</div></div><div><h3>Results</h3><div>A total of 128 patients were enrolled at 13 centers in mainland China, with a median age of 74 years (Q1-Q3: 70-78 years) and a median Society of Thoracic Surgeons Predicted Risk of Mortality score of 4.84% (Q1-Q3: 4.21%-6.47%). Procedural success was achieved in 123 of 128 patients (96.09%), with a median oversizing ratio of 5.10% (Q1-Q3: 2.69%-6.83%) and a median implantation depth of 5 mm (Q1-Q3: 2-6 mm). Valve migration occurred in 3 of 128 cases, with 2 of 128 patients undergoing second valve implantation and 1 of 128 converting to surgery. Within the 30-day follow-up, 15 of 125 patients (12.00%) required new permanent pacemaker implantation, 1 of 128 patients (0.78%) experienced a major bleeding event, and 3 of 128 patients (2.34%) died. At 30-day follow-up, none of the patients had intravalvular aortic regurgitation or more than mild paravalvular regurgitation. The median effective orifice area was 2.50 cm² (Q1-Q3: 2.20-2.98 cm²). Significant improvements were observed in NYHA functional class (<em>P</em> &lt; 0.001) and EQ-5D score (<em>P</em> &lt; 0.001). Moreover, significant reductions were observed in left ventricular end-diastolic diameter (<em>P</em> &lt; 0.001) and left ventricular end-systolic diameter (<em>P</em> &lt; 0.001) at 30-day follow-up, while there was an increase in left ventricular ejection fraction (<em>P</em> = 0.007).</div></div><div><h3>Conclusions</h3><div>The early results of the HAVE AR trial showed a low incidence of adverse safety events, especially low permanent pacemaker implantation rate, and good efficacy of the Hanchor Valve system for treating patients with severe PNAR at intermediate or high surgical risk.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 752-764"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"1-Year Real-World Outcomes of TAVR With the Fifth-Generation Balloon-Expandable Valve in the United States","authors":"Annapoorna S. Kini MD ,&nbsp;Gilbert H.L. Tang MD, MSc, MBA ,&nbsp;Ricardo Yaryura MD ,&nbsp;George Petrossian MD ,&nbsp;David K. Roberts MD ,&nbsp;Ayaz Rahman MD ,&nbsp;Adam Saltzman MD ,&nbsp;Raymond Durkin MD ,&nbsp;James T. DeVries MD ,&nbsp;Curtiss Stinis MD","doi":"10.1016/j.jcin.2024.11.015","DOIUrl":"10.1016/j.jcin.2024.11.015","url":null,"abstract":"<div><h3>Background</h3><div>Longer term outcomes of transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 Ultra RESILIA (S3UR) valve over its predecessors have not been reported in a national registry.</div></div><div><h3>Objectives</h3><div>The aim of this study was to compare the 1-year clinical and echocardiographic outcomes of the S3UR with those of the SAPIEN 3 (S3) and SAPIEN 3 Ultra (S3U) in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry.</div></div><div><h3>Methods</h3><div>From September 2022 to March 2023, patients who underwent native TAVR with the S3UR or the S3 or S3U valve were propensity matched and compared. Predictors of 1-year outcomes were identified. The median follow-up time was 358 days (Q1-Q3: 47-365 days) for the S3UR and 364 days (Q1-Q3: 80-365 days) for the S3 and S3U.</div></div><div><h3>Results</h3><div>A total of 4,598 S3UR patients were propensity matched with 4,598 and 32,536 S3 and S3U patients. At discharge, effective orifice areas were larger in the S3UR group (<em>P</em> &lt; 0.0001). The lower discharge mean gradient in the S3UR group was maintained at 30 days and 1 year (<em>P</em> &lt; 0.0001 for all). At 1 year, all-cause mortality (7.6% vs 9.7%; HR: 0.8; 95% CI: 0.67-0.93; <em>P</em> = 0.004), mild or greater paravalvular leak (PVL) (15.6% vs 18.5%; HR: 0.82; 95% CI: 0.69-0.97; <em>P</em> = 0.02), and life-threatening bleeding (2.0% vs 2.7%; HR: 0.7; 95% CI: 0.54-0.94; <em>P</em> = 0.03) were lower in the S3UR group. S3UR and mild or greater PVL were predictive of 1-year mortality in the overall cohort and in low-risk patients. Valve reintervention remained rare at 1 year (0.6% vs 0.4%; HR: 1.46; 95% CI: 0.77-2.78; <em>P</em> = 0.25).</div></div><div><h3>Conclusions</h3><div>TAVR with the S3UR is associated with superior 1-year clinical outcomes and lower gradients than its predecessors, with less PVL and low valve reintervention. Longer follow-up will determine the durability of the RESILIA technology in the SAPIEN valve platform.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 785-797"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142758696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Lifetime Coronary Access After TAVR","authors":"Arif A. Khokhar BM, BCh ,&nbsp;Alessandro Beneduce MD ,&nbsp;Claudio Guerreiro MD ,&nbsp;Jonathan Curio MD ,&nbsp;Adriana-Zlahoda Huzior MSc ,&nbsp;Francesco Giannini MD ,&nbsp;Ole De Backer MD, PhD ,&nbsp;Rui Teles MD ,&nbsp;Dariusz Dudek MD, PhD","doi":"10.1016/j.jcin.2024.10.059","DOIUrl":"10.1016/j.jcin.2024.10.059","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 800-803"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TAVR and the Continuous Quest for Improvement","authors":"Anita W. Asgar MD, MSc","doi":"10.1016/j.jcin.2024.12.026","DOIUrl":"10.1016/j.jcin.2024.12.026","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 798-799"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a Novel BifurcAID Risk Score to Predict MACE Following Coronary True Bifurcation Intervention","authors":"Shingo Minatoguchi MD ,&nbsp;Anoop N. Koshy MBBS, PhD ,&nbsp;Yuliya Vengrenyuk PhD ,&nbsp;Manish Vinayak MD ,&nbsp;Keisuke Yasumura MD ,&nbsp;Raman Sharma MD ,&nbsp;Parasuram Krishnamoorthy MD ,&nbsp;Javed Suleman MD ,&nbsp;Joseph Sweeny MD ,&nbsp;Amit Hooda MD ,&nbsp;Vishal Kapur MD ,&nbsp;Roxana Mehran MD ,&nbsp;Samin K. Sharma MD ,&nbsp;Annapoorna S. Kini MD","doi":"10.1016/j.jcin.2024.11.034","DOIUrl":"10.1016/j.jcin.2024.11.034","url":null,"abstract":"<div><h3>Background</h3><div>Percutaneous coronary intervention (PCI) for true bifurcation lesions is associated with a higher risk of adverse clinical events.</div></div><div><h3>Objectives</h3><div>This study sought to establish a point-based score using clinical and angiographic characteristics in true bifurcation lesions before PCI to predict the risk of major adverse cardiovascular events (MACE).</div></div><div><h3>Methods</h3><div>A total of 1,896 consecutive patients undergoing PCI for true bifurcation lesions between 2012 and 2019 in our institution were included. All angiograms were reviewed by an independent core laboratory for classification of the bifurcation lesions. A multivariate model identified factors associated with 1-year MACE, comprising all-cause death, myocardial infarction, and target vessel revascularization. Points were assigned to each risk factor proportional to their regression coefficients to create a cumulative risk score. The score was used to stratify patients into low-, intermediate-, and high-risk cohorts.</div></div><div><h3>Results</h3><div>At 1-year post-PCI, MACE occurred in 185 patients (9.8%). Eleven predictors of MACE were identified: 5 clinical (insulin-dependent diabetes mellitus, left ventricular ejection fraction ≤30%, non–ST-segment elevation myocardial infarction presentation, age &gt;80 years, and non-white race/ethnicity), and 6 angiographic (left main or left circumflex-obtuse marginal coronary artery lesion, multivessel disease, side branch [SB] thrombus, SB moderate/severe calcium, and SB lesion length &gt;10 mm). The rate of MACE was 4.9% in low-risk patients with a risk score 0 to 6 (reference group), 12.9% in intermediate-risk patients with a score 7 to 9 (OR: 2.63; 95% CI: 1.74-3.98; <em>P</em> &lt; 0.001), and 25.4% in high-risk group with a score ≥10 (OR: 5.18; 95% CI: 3.56-7.53; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The BifurcAID risk score may facilitate risk stratification among patients undergoing true bifurcation PCI and guide patient-tailored treatment strategies.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 705-716"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paravalvular Leak Closure After Transcatheter Tricuspid Valve Replacement","authors":"Amr Gamal MD, MSc,&nbsp;Alex Patrascu MD, PhD,&nbsp;Thomas Attumalil MD,&nbsp;Mohammed Alkasab MD,&nbsp;Bryan Traynor MD,&nbsp;Yazeed Almalki MD,&nbsp;Geraldine Ong MD, MSc,&nbsp;Sami Alnasser MD,&nbsp;Neil P. Fam MD, MSc","doi":"10.1016/j.jcin.2024.11.027","DOIUrl":"10.1016/j.jcin.2024.11.027","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 813-814"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Use of Intra-Aortic 3D ICE to Guide Ascending Aorta Pseudoaneurysm Repair","authors":"Erica Scherer BS ,&nbsp;Avery Kerwin BA ,&nbsp;Jonathan Schwartz MD ,&nbsp;Markus Scherer MD","doi":"10.1016/j.jcin.2024.11.022","DOIUrl":"10.1016/j.jcin.2024.11.022","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 811-812"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plus Anchor Valve Replacement for Treatment of Severe Aortic Regurgitation With an Extremely Large Annulus","authors":"Wei Zhong MD ,&nbsp;Wenzhi Pan MD ,&nbsp;Zhidong Liu MD ,&nbsp;Youhong Zhang MD ,&nbsp;Zhiyuan Liu MD ,&nbsp;Youqian Li MD ,&nbsp;Changjing Huang MD ,&nbsp;Yanxing Fang MB ,&nbsp;Zhixiong Zhong MD","doi":"10.1016/j.jcin.2024.11.030","DOIUrl":"10.1016/j.jcin.2024.11.030","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 6","pages":"Pages 808-810"},"PeriodicalIF":11.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}